Rapid Therapeutic Valuation
| RTSL Stock | USD 0 0.00 0.00% |
Rapid Therapeutic seems to be overvalued based on Macroaxis valuation methodology. Our model determines the value of Rapid Therapeutic Science from analyzing the company fundamentals such as Shares Owned By Insiders of 66.33 %, return on asset of -0.55, and Gross Profit of 334 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Rapid Therapeutic's price fluctuation is out of control at this time. Calculation of the real value of Rapid Therapeutic Science is based on 3 months time horizon. Increasing Rapid Therapeutic's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Rapid pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Rapid Therapeutic Science. Since Rapid Therapeutic is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Rapid Pink Sheet. However, Rapid Therapeutic's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.002 | Real 0.001701 | Hype 0.002164 | Naive 0.002072 |
The intrinsic value of Rapid Therapeutic's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Rapid Therapeutic's stock price.
Estimating the potential upside or downside of Rapid Therapeutic Science helps investors to forecast how Rapid pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Rapid Therapeutic more accurately as focusing exclusively on Rapid Therapeutic's fundamentals will not take into account other important factors: Rapid Therapeutic Total Value Analysis
Rapid Therapeutic Science is at this time projected to have valuation of 13.08 M with market capitalization of 4.22 M, debt of 150 K, and cash on hands of 112.16 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Rapid Therapeutic fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
13.08 M | 4.22 M | 150 K | 112.16 K |
Rapid Therapeutic Investor Information
About 66.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.51. Rapid Therapeutic Science had not issued any dividends in recent years. The entity had 1:25 split on the 31st of March 2022. Based on the measurements of operating efficiency obtained from Rapid Therapeutic's historical financial statements, Rapid Therapeutic Science is not in a good financial situation at this time. It has a very high probability of going through financial hardship in February.Rapid Therapeutic Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Rapid Therapeutic has an asset utilization ratio of 0.0243 percent. This suggests that the Company is making $2.43E-4 for each dollar of assets. An increasing asset utilization means that Rapid Therapeutic Science is more efficient with each dollar of assets it utilizes for everyday operations.Rapid Therapeutic Ownership Allocation
Rapid Therapeutic holds majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 66.33 pct. of Rapid Therapeutic Science outstanding shares that are owned by insiders implies they have been buying or selling the stock in recent months in anticipation of some upcoming event.Rapid Therapeutic Profitability Analysis
The company reported the previous year's revenue of 534. Net Loss for the year was (2.87 M) with profit before overhead, payroll, taxes, and interest of 334.About Rapid Therapeutic Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Rapid Therapeutic Science. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Rapid Therapeutic Science based exclusively on its fundamental and basic technical indicators. By analyzing Rapid Therapeutic's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Rapid Therapeutic's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Rapid Therapeutic. We calculate exposure to Rapid Therapeutic's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Rapid Therapeutic's related companies.Rapid Therapeutic Science Laboratories, Inc. operates as a biotech company. Rapid Therapeutic Science Laboratories, Inc. was a former subsidiary of Texas Mdi, Inc. Rapid Therapeutic operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 8 people.
8 Steps to conduct Rapid Therapeutic's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Rapid Therapeutic's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Rapid Therapeutic's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Rapid Therapeutic's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Rapid Therapeutic's revenue streams: Identify Rapid Therapeutic's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Rapid Therapeutic's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Rapid Therapeutic's growth potential: Evaluate Rapid Therapeutic's management, business model, and growth potential.
- Determine Rapid Therapeutic's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Rapid Therapeutic's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Rapid Therapeutic Growth Indicators
Investing in growth stocks can be very risky. If the company such as Rapid Therapeutic does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 2.4 M | |
| Retained Earnings | -8.5 M |
Other Information on Investing in Rapid Pink Sheet
Rapid Therapeutic financial ratios help investors to determine whether Rapid Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rapid with respect to the benefits of owning Rapid Therapeutic security.